Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

Potential Efficacy in Huntington's Disease Already Demonstrated

NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD"). Cysteamine is currently approved by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare lysosomal storage disease. Preclinical results suggest that cysteamine has neuroprotective effects that could potentially help treat HD. Raptor's clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), plans to evaluate cysteamine in patients with HD.

HD is a rare and hereditary neurological disease thought to occur in approximately 1 out of every 20,000 people resulting in around 20,000 patients in the U.S. presently. There is currently no drug available that targets the unique molecular defect that is believed to cause HD, a progressive disease that often leads to death within 15 to 20 years after diagnosis. HD is caused by a defective gene resulting in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia. Preclinical findings on cysteamine's mechanism of action suggest that it has neuroprotective effects by increasing the levels of BDNF, a neuroprotective neurotrophic factor, in the brain of HD mice. BDNF levels may also be a potential biomarker of efficacy for cysteamine in HD, an important development issue when a therapy is used to prevent or slow clinical manifestation of a disorder.

The 1983 Orphan Drug Act provides important economic incentives to encourage companies to develop potential therapies for the diagnosis, prevention and/or treatment of rare, serious diseases affecting 200,0
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... , June 26, 2015 The ... Application (Hydraulic Fluids, Metalworking fluids, Chainsaw oils, Mold Release ... by Region - Global trends and Forecasts to 2020" ... reach $2,972.13 Million by 2020 at a CAGR of ... 160 market data Tables and   66 Figures spread ...
(Date:6/25/2015)... , June 25, 2015 ... ) has announced the addition of ... the Global Cancer Diagnostics Industry: Oncogenes, ... Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/25/2015)... ... 25, 2015 , ... Students entering the new Hemenway Hall ... each exclusively using filtered fume hoods that feature Erlab’s GreenFumeHood Filtration Technology ... hoods needed for their Organic, Inorganic, Analytical, and Physical Chemistry teaching laboratories. Each ...
(Date:6/25/2015)... England , June 25, 2015 /PRNewswire/ ... von Arzneimittel-Überprüfungs- und -Authentifizierungsdienstleistungen, führte am 24. ... Frankfurt am Main das 2. ... umfassende Informations-Veranstaltung zum Thema Sicherheit für Patienten ... -.      (Logo: http://photos.prnewswire.com/prnh/20150610/748687) , ...
Breaking Biology Technology:Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2Symposium zur Richtlinie über gefälschte Arzneimittel - mit Aegate in Deutschland 2Symposium zur Richtlinie über gefälschte Arzneimittel - mit Aegate in Deutschland 3
... 6 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin ... leading manufacturer and distributor,of high-quality, pharmaceutical grade ... products that serve as raw materials for ... it will conduct a conference,call at 9:00 ...
... Expands the Company,s Clinical Stage Product Portfolio ... Meditrina Pharmaceuticals,Inc. today announced that it ... make, develop and commercialize products under AstraZeneca,s ... inhibitors (AI) in combination with,estrogen and progestin ...
... Inc. ("Senesco" or the "Company") (Amex: SNT ... focused on multiple myeloma that,were conducted concurrently at ... of these studies, which utilized two different dosing ... Factor 5A technology to induce,apoptosis in tumors. Additionally, ...
Cached Biology Technology:Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 2Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3
(Date:6/12/2015)... 2015  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announced the United ... capture, analyze and identify participants of a video ... This system can: , Identify ... subsequent sign-on process is actually the person participating ...
(Date:6/9/2015)... Minn. , June 9, 2015   MedNet ... supports the entire spectrum of clinical research, will be ... eClinical technology platform at the 2015 Drug Information Association ... on June 15-17.  These presentations will include previews ... rolled out in the upcoming iMedNet 2015 ...
(Date:6/8/2015)... June 8, 2015  The Secure Identity ... selection of Troy Potter of L-3 ... SIBA is a non-profit association that was established ... education and implementation of solutions that protect and ... ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... VANCOUVER, BRITISH COLUMBIA Parents of children with chronic ... to a study being presented Monday, May 3 at ... British Columbia, Canada. Medication use in children with ... been done on mistakes made by parents giving these ...
... in complex networks that govern cellular processes, much like people ... discovering how biological networks change and are rewired in cancer. ... ( www.genome.org ), scientists have analyzed the genetic networks ... awry in disease. MicroRNAs (miRNAs) are short RNA molecules ...
... , STANFORD, Calif. - Life is almost unbearably complex. ... and off in dizzying combinations and sequences during their ... to understand the machinations of the proteins behind the ... their disposal, courtesy of researchers at the Stanford University ...
Cached Biology News:Home medication errors common among children with chronic conditions 2MicroRNA network study implicates rewired interactions in cancer 2New Stanford tool enables wider analyses of genome 'deep sequencing' 2New Stanford tool enables wider analyses of genome 'deep sequencing' 3
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
... NIS-Elements revolutionizes imaging software for the ... to microscopes, cameras, components and peripherals ... achiving tools. Its intuitive interface simplifies ... times while providing powerful features such ...
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
Biology Products: